Journal of diabetes investigation 2018 02 10() doi 10.1111/jdi.12817
Hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) fluctuate throughout the year. However, there are few studies that have evaluated the therapeutic effect of hypoglycemic agents while considering such fluctuations. In a multi-center study (JAMP Study), pre-treatment patients with T2DM were divided into seven groups and administered sitagliptin for 1 year. The aim of this study was to evaluate the differences in the therapeutic effect, and efficacy, of sitagliptin in patients with T2DM based on the month administration of the drug began as sub-analysis of the JAMP Study.
MATERIALS AND METHODS
Patients with T2DM were divided into four groups according to the month of initiation of sitagliptin. Changes in HbA1c in each group were compared at 3 months and 12 months after administration of sitagliptin. Since a negative correlation has been reported between baseline HbA1c and degree of change after administration of sitagliptin, an analysis using the residual error from the approximate line was performed.
In the analysis of the degree of change in HbA1c, patients in the group in which administration of sitagliptin was started between August and October had the lowest degree of improvement at 3 months after starting sitagliptin. However, there was no significant intergroup difference in improvement at 12 months after the start of sitagliptin. The same result was also obtained in residual analysis.
This study suggested that the season of administration of sitagliptin influenced subsequent hypoglycemic effect even after analysis excluding the influence of HbA1c value at the start of treatment. This study provides possibility, indicating that seasonal fluctuations have an effect on the efficacy of antidiabetic drugs. This article is protected by copyright. All rights reserved.